Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Sebastian Cummins"'
Autor:
Richard J. Ellis, Harpreet Wasan, Karen McAdam, S. Arif, Lisa Bax, Roopinder Gillmore, Jonathan Wadsley, Duncan I. Jodrell, Sebastian Cummins, Albrecht Neesse, Pippa Corrie, Yuk Ting Ma, Daniel H. Palmer, Rebecca Brais, J. Evans, David Propper, Aarthi Gopinathan, A. Chhabra, Martin Scott-Brown, R. Skells, Andrea Machin, K. Dalchau, A. Dayim, P. Bundi, Christopher Isherwood, Bristi Basu, C. Lwuji, John Bridgewater, David A. Tuveson, Alan Anthoney, Lucy Wall, S Falk, Juan W. Valle, Wendi Qian
Publikováno v:
British Journal of Cancer
Corrie, P G, Qian, W, Basu, B, Valle, J, Falk, S, Iwuji, C, Wasan, H, Palmer, D, Scott-Brown, M, Wadsley, J, Arif, S, Bridgewater, J, Propper, D, Gillmore, R, Gopinathan, A, Skells, R, Bundi, P, Brais, R, Dalchau, K, Bax, L, Chhabra, A, Machin, A, Dayim, A, McAdam, K, Cummins, S, Wall, L, Ellis, R, Anthoney, A, Evans, J, Ma, Y T, Isherwood, C, Neesse, A, Tuveson, D & Jodrell, D I 2020, ' Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma ', BJC, vol. 122, pp. 1760–1768 . https://doi.org/10.1038/s41416-020-0846-2
Corrie, P G, Qian, W, Basu, B, Valle, J, Falk, S, Iwuji, C, Wasan, H, Palmer, D, Scott-Brown, M, Wadsley, J, Arif, S, Bridgewater, J, Propper, D, Gillmore, R, Gopinathan, A, Skells, R, Bundi, P, Brais, R, Dalchau, K, Bax, L, Chhabra, A, Machin, A, Dayim, A, McAdam, K, Cummins, S, Wall, L, Ellis, R, Anthoney, A, Evans, J, Ma, Y T, Isherwood, C, Neesse, A, Tuveson, D & Jodrell, D I 2020, ' Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma ', BJC, vol. 122, pp. 1760–1768 . https://doi.org/10.1038/s41416-020-0846-2
Background Nab-paclitaxel plus gemcitabine (nabP+gemcitabine) offers modest survival gains for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Sequential scheduling of nabP+gemcitabine in a PDAC mouse model improved efficacy; this h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9399cbe124eda4393bc1c1e2297d6732
Autor:
Mohammed Abdul Imran Khan, Tania Tillett, Rajarshi Roy, Simon Lord, Zuzana Stokes, Helen Howard, Matthew T. Seymour, Christine Allmark, C. Handforth, Guptal Kamalnayan, Jonathan Nicoll, Eszter Katona, Joseph Mano, Sharon Ruddock, Nick Maisey, David A Cairns, Galina Velikova, Ángel David Roncancio García, Jonathan Wadsley, Anirban Chatterjee, Peter Hall, Daniel Swinson, Stephen Falk, Pei Loo Ow, Helen Marshall, Simon Grumett, Sebastian Cummins, Heike I. Grabsch, Jo Dent, Kamposioras Kostantinos-Vellios, Justin Waters, Russell D. Petty, Anne Crossley, Thomas K. Waddell
Publikováno v:
SSRN Electronic Journal.
Background: GO2 sought to optimise chemotherapy dosing in older/frail patients with advanced gastroesophageal cancer, and explored baseline geriatric assessment (GA) as a tool for treatment decision-making. Methods: Patients were recruited for whom f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c59fb829c1f7be74d57753c59513f2eb
https://doi.org/10.2139/ssrn.3724274
https://doi.org/10.2139/ssrn.3724274
Autor:
Pei Loo Ow, Angel Garcia, Lesley Samuel, Rajarshi Roy, Adam McGeoch, D. Fyfe, W Saku, Simon Aird Grumett, Jonathan Nicoll, Jo Dent, Tom Samuel Waddell, Jo Webster, Christine Allmark, Tania Tillett, Colin Askill, Justin S. Waters, C. Handforth, Erica Beaumont, Vallipuram Vigneswaran, Sharon Ruddock, Nick Wadd, Syed Zubair, Kinnari Patel, Vanessa Potter, Daniel Propper, Olwyn Williams, Marc Jones, Kamalnayan Guptal, Peter Hall, Gareth Griffiths, Joseph Mano, Juan W. Valle, Sheela Rao, David A Cairns, Go Trial Investigators, Eszter Katona, Nick Maisey, Chris Twelves, Daniel Swinson, Nicholas Reed, Heike I. Grabsch, Joanne Askey, Jonathan Wadsley, Tom Roques, Sue Cheeseman, Stephen Falk, Louise Medley, Arshad Jamil, Emma Cattell, Victori Kunene, Matthew R. Sydes, Charles Candish, Claire Hobbs, Rebecca Herbertson, Jo Parkinson, Nicholas S. Reed, Louise Brook, Zuzana Stokes, Mohammed Khan, Ann Crossley, Elin Jones, George Bozas, Sebastian Cummins, Anirban Chatterjee, Michael Bennet, Helen Marshall, Pavel Bezecny, David Sherriff, Matthew T. Seymour, Lauren Gorf, Galina Velikova, Jean Gall, Kamposioras Konstantinos-Velios, Sally Clive, Eleanor James, Fiona Collinson, Dunca Wilkins, Simon Lord, Julia Brown, Serena Hilman, A. Robinson, Richard Ellis, Alaaeldin Shablak, Russell D Petty, Sherif Raouf, Helen Howard
Publikováno v:
Hall, P S, Swinson, D, A. Cairns, D, S. Waters, J, Petty, R, Allmark, C, Ruddock, S, Falk, S, Wadsley, J, Roy, R, Tillett, T, Nicoll, J, Cummins, S, Mano, J, Grumett, S, Stokes, Z, Konstantinos-Velios, K, Chatterjee, A, Garcia, A, Waddell, T, Guptal, K, Maisey, N, Khan, M, Dent, J, Lord, S, Crossley, A, Katona, E, Marshall, H, I. Grabsch, H, Velikova, G, Loo Ow, P, Handforth, C, Howard, H & T. Seymour, M 2021, ' Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal CancerThe GO2 Phase 3 Randomized Clinical Trial ', JAMA Oncology . https://doi.org/10.1001/jamaoncol.2021.0848
JAMA Oncology, 7(6), 869-877. American Medical Association
JAMA Oncology, 7(6), 869-877. American Medical Association
Importance: Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap. Objective: The GO2 randomized clinical trial sought to optimize chemotherapy dosing in older and/or frai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::957a450457d575d4bca5b7ef992b410c
https://doi.org/10.1001/jamaoncol.2021.0848
https://doi.org/10.1001/jamaoncol.2021.0848
Autor:
Heike I. Grabsch, David Cunningham, Nicholas P. West, Ruth E Langley, William H. Allum, Joyce Thompson, Avani Athauda, Naureen Starling, Erica Beaumont, Susan Pritchard, Fareeda Y. Coxon, Matthew Nankivell, Stephen Falk, Adrian Crellin, Suzanne Darby, Wasat Mansoor, Rupert Langer, D Alderson, Sebastian Cummins, Ian Chau
Publikováno v:
Journal of Clinical Oncology. 37:4022-4022
4022 Background: No large scale randomised data exists evaluating the impact of age and sex in patients (pts) undergoing potentially curative surgery and CTx for OG cancer. However, differences in age and sex may be contributing factors to variabilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::688abb126c5c7431e006f55681cb4081
https://doi.org/10.1200/jco.2019.37.15_suppl.4022
https://doi.org/10.1200/jco.2019.37.15_suppl.4022
Autor:
Rajarshi Roy, Ricky A. Sharma, Lucy Wills, Andrew Bateman, Sarah Gwynne, R. Maggs, Stephen Falk, Sebastian Cummins, S. Gollins, Maria A. Hawkins, S. Mukherjee, Emiliano Spezi, Heike I. Grabsch, Tom Crosby, Ganesh Radhakrishna
Publikováno v:
Clinical Oncology. 25:368-377
The SCOPE 1 trial closed to recruitment in early 2012 and has demonstrably improved the quality of UK radiotherapy. It has also shown that there is an enthusiastic upper gastrointestinal clinical oncology community that can successfully complete tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afc227a596e06799a10646b2a3c34c92
https://doi.org/10.1016/j.clon.2013.01.006
https://doi.org/10.1016/j.clon.2013.01.006
Autor:
Jakob R. Izbicki, Gary Middleton, Alan Anthoney, Paula Ghaneh, Harpreet Wasan, Kinnari Patel, David Cunningham, Olusola Olusesan Faluyi, Rubin Soomal, Thilo Hackert, John P. Neoptolemos, Christopher Halloran, Derek A. O'Reilly, Alec McDonald, Jonathan Wadsley, Yuk Ting Ma, Eftychia E. Psarelli, David Sherriff, Pascal Hammel, Markus W. Büchler, David Borg, Bengt Glimelius, Juan W. Valle, Roopinder Gillmore, Sharmila Sothi, Pehr Lind, Daniel H. Palmer, Tom Crosby, Tim Meyer, Richard J. Jackson, Paul Ross, Suzanne Darby, Stephen Falk, Sebastian Cummins
Publikováno v:
Lancet
Lancet (London, England)
European Study Group for Pancreatic Cancer 2017, ' Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. ', The Lancet, vol. 389, no. 10073, pp. 1011-1024 . https://doi.org/10.1016/S0140-6736(16)32409-6
Lancet (London, England)
European Study Group for Pancreatic Cancer 2017, ' Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. ', The Lancet, vol. 389, no. 10073, pp. 1011-1024 . https://doi.org/10.1016/S0140-6736(16)32409-6
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::672ef8f5ee017a21dda65b9a696aceaf
https://pubmed.ncbi.nlm.nih.gov/30842047
https://pubmed.ncbi.nlm.nih.gov/30842047
Publikováno v:
European Urology. 57:673-678
Background Following orchidectomy patients with stage I seminoma of the testis may be managed by either surveillance or adjuvant treatment. In view of the very high cure rate, it is important to analyse long-term outcomes. Objective : To provide data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c50c4426b06ddedf7db95a71e03439ad
https://doi.org/10.1016/j.eururo.2009.06.006
https://doi.org/10.1016/j.eururo.2009.06.006
Autor:
Rajarshi Roy, Thomas Crosby, Alec McDonald, Stephen Falk, Sebastian Cummins, Ruby Ray, Gareth Griffiths, George Joseph, Harpreet Wasan, Ross A. Abrams, Ganesh Radhakrishna, John Staffurth, Catherine Jephcott, Somnath Mukherjee, Chris Nicholas Hurt, Tim Maughan, John Bridgewater
Publikováno v:
The Lancet Oncology
BACKGROUND: In the UK, chemotherapy is the standard treatment for inoperable, locally advanced, non-metastatic pancreatic cancer. Chemoradiotherapy is also an acceptable treatment option, for which gemcitabine, fluorouracil, or capecitabine can be us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94a57a6ce81aecd467f9916610c95ec9
https://orca.cardiff.ac.uk/id/eprint/46616/1/OA-84.pdf
https://orca.cardiff.ac.uk/id/eprint/46616/1/OA-84.pdf
Autor:
Sebastian Cummins, Tim Meyer, Faluyi Olusola, Lucy Wall, Juan W. Valle, John Ramage, Ruby Saharan, Andrea Frilling, Johnathan Wadsley, Gaurav Kapur, Pankaj Punia, Naureen Starling, David Farrugia, Judith Cave
Publikováno v:
Annals of Oncology. 27:vi143
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9470c74a170c55acbbc9b7bc38fb0430
https://doi.org/10.1093/annonc/mdw369.22
https://doi.org/10.1093/annonc/mdw369.22
Autor:
G. Radhakrishna, Ruby Ray, John Staffurth, Tim Maughan, John Bridgewater, Tom Crosby, C Jephcott, Harpreet Wasan, Gareth Griffiths, S. Mukherjee, Stephen Falk, R. Roy, Chris Nicholas Hurt, Sebastian Cummins, Ross A. Abrams, Alec McDonald, G. Joseph
Publikováno v:
Annals of Oncology. 27:ii118
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2783d1aa6dc9e4e4949cb0cb0a8b4e7b
https://doi.org/10.1093/annonc/mdw198.03
https://doi.org/10.1093/annonc/mdw198.03